First Results with Erdafitinib-Releasing Intravesical : comp

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery...

Related Keywords

Vilaseca , Comunidad Autonoma De Cataluna , Spain , Madrid , Belgium , Beerse , Region Flamande , Barcelona , Indianj Urol , Janssen Cilag Gmb , Janssen Pharmaceutica , Jeffrey Infante , Martin Vogel , Urology Care Foundation , Janssen Research Development , None Of The Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , European Society For Medical Oncology , Astex Therapeutics , Oncology Early Clinical Development , Translational Research , Astex Announces New Drug Discovery Alliance , Janssen Pharmaceutical Companies , Johnson , Exchange Commission , Companies Of Johnson , Late Breaking Mini Oral Presentation Session , European Society , Medical Oncology , Area Lead Oncology , Bacillus Calmette Gu , Global Head , Janssen Research , Astex Therapeutics Limited , Pharmaceutical Companies , Pulmonary Hypertension , Janssen Cilag Gmbh , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Efficacy Results , Intravesical Delivery System , Muscle Invasive Bladder Cancer , With Select , Erdafitinib Intravesical Delivery System , Localized Bladder , Erdafitinib Versus Investigator Choice , Participants Who Received Bacillus Calmette Gu , Participants With Metastatic , Locally Advanced Urothelial , Participants With Advanced Solid Tumors , Fibroblast Growth Factor Receptor , Gene Alterations , Erdafitinib Compared With Vinflunine , Participants With Advanced Urothelial Cancer , Selected Fibroblast Growth Factor Receptor , Gene Aberrations , Non Muscle Invasive Bladder , Janssen Emea ,